Introduction
Epiphora is a clinical condition characterized by excessive tearing or overflow of tears onto the facial skin, often accompanied by a watery discharge. It may arise from dysfunction of the lacrimal apparatus, including the lacrimal glands, puncta, canaliculi, or nasolacrimal duct. While mild epiphora is common and frequently self-limiting, persistent or severe cases can compromise ocular comfort, vision, and quality of life. The term derives from the Greek words epi (upon) and phoros (to carry), reflecting the overt overflow of tears that occurs on the face.
Etymology and Terminology
The word “epiphora” first appeared in medical literature in the 19th century, denoting the observable excess of tears. In clinical practice, it is often used synonymously with “lacrimal overflow” or “lacrimal hypersecretion.” Diagnostic terminology distinguishes epiphora from other tear-related disorders such as keratoconjunctivitis sicca (dry eye syndrome) or ocular surface inflammation. Precise language is essential when documenting the underlying etiology, whether obstructive, hypersecretory, or reflex in nature.
Anatomy and Physiology of Tear Production
Lacrimal Glands
The primary source of aqueous tears is the paired lacrimal glands, located in the superolateral orbit. They secrete fluid rich in electrolytes, proteins, and mucins, which lubricates the ocular surface and provides a defense against pathogens. The secretion rate is regulated by both sympathetic and parasympathetic innervation, as well as hormonal influences.
Puncta, Canaliculi, and Nasolacrimal Duct
Tears drain from the ocular surface through the puncta - small openings at the inner eyelid margins. The canaliculi transport fluid into the lacrimal sac, which then channels it into the nasolacrimal duct, ultimately emptying into the inferior meatus of the nasal cavity. The coordinated action of these structures maintains tear turnover, normally averaging 0.1–0.5 mL per eye per day. Any disruption along this pathway can produce epiphora.
Pathophysiology of Epiphora
Obstructive Mechanisms
Partial or complete blockage of the nasolacrimal duct or its tributaries impedes drainage, leading to increased tear volume on the ocular surface. Obstruction may be congenital (e.g., nasolacrimal duct cysts) or acquired, often from inflammation, fibrosis, or neoplastic invasion. The resulting pressure gradient can cause tears to overflow across the eyelid margin.
Hypersecretory States
Hyperactivity of the lacrimal gland can produce excess tears independent of drainage impairment. Reflex tearing may be triggered by irritants such as wind, smoke, or ocular surface trauma. In some systemic conditions, such as Sjögren’s syndrome or thyroid eye disease, the glandular secretory activity is altered, potentially contributing to epiphora.
Functional Ductal Dysregulation
Even in the absence of anatomic blockage, functional dysfunction - such as spasm or incomplete contraction of the lacrimal drainage system - can impede tear outflow. The precise mechanisms remain an active area of research, involving complex neurovascular regulation.
Causes
Obstruction of the Nasolacrimal Duct
- Congenital nasolacrimal duct obstruction (persistent infant epiphora)
- Acquired obstruction from inflammation (e.g., dacryocystitis, allergic rhinitis)
- Fibrosis or scarring post‑surgery or trauma
- Neoplastic lesions (e.g., nasolacrimal duct carcinoma, metastatic disease)
Dysfunction of the Lacrimal Gland
- Hypersecretory states (reflex tearing due to irritants)
- Autoimmune conditions (Sjogren’s syndrome, rheumatoid arthritis)
- Hormonal imbalances (thyroid disease, pregnancy)
Inflammation and Infection
- Dacryoadenitis (inflammation of the lacrimal gland)
- Dacryocystitis (infection of the lacrimal sac)
- Conjunctivitis or blepharitis leading to reflex tearing
Trauma
- Facial fractures involving the lacrimal system (e.g., orbital floor fractures)
- Soft‑tissue injuries disrupting punctal or canalicular integrity
Systemic Diseases
- Rheumatologic disorders (e.g., lupus, sarcoidosis)
- Infectious diseases (e.g., tuberculosis, HIV-associated lacrimal gland disease)
- Neoplastic processes involving the orbit or nasolacrimal duct
Idiopathic
In a minority of patients, epiphora persists without an identifiable cause after thorough evaluation. These cases are often managed empirically, focusing on symptom relief.
Diagnosis
Clinical Evaluation
History taking should emphasize symptom onset, duration, precipitating factors, and associated visual disturbances. Physical examination focuses on the eyelid margins, punctal patency, and the presence of discharge. A slit‑lamp examination may reveal conjunctival hyperemia, corneal staining, or punctal swelling.
Imaging
Radiologic modalities are valuable when obstruction is suspected. Contrast dacryocystography (CDG) provides detailed visualization of the lacrimal drainage system. CT or MRI may identify mass lesions or bone remodeling. Ultrasound biomicroscopy can assess canalicular anatomy in pediatric patients.
Functional Tests
- Water‑drainage test (WDT) to assess drainage efficiency by observing the time for a water droplet to exit the punctum.
- Schirmer’s test to quantify tear production and differentiate hypersecretion from hyposecretion.
- Punctal occlusion tests to evaluate the contribution of punctal stenosis.
Management and Treatment
Medical Management
Conservative measures are often first line for mild epiphora. These include lubricating eye drops, warm compresses to relieve ductal inflammation, and topical anti‑inflammatory agents (e.g., cyclosporine). In cases of infection, appropriate antibiotics (topical or systemic) are indicated.
Procedural Interventions
- Punctal plugs to restrict tear drainage when obstruction is minimal.
- Endoscopic dacryocystorhinostomy (DCR) to create a direct drainage pathway between the lacrimal sac and the nasal cavity, commonly used for nasolacrimal duct obstruction.
- Canalicular dilatation or intubation for canalicular stenosis or laceration.
- Excisional surgery for tumorous causes or severe scarring.
Emerging Therapies
Recent studies explore regenerative approaches, such as lacrimal gland stem cell transplantation, to restore secretory function. Additionally, neurostimulation devices are being evaluated for functional dysregulation of the lacrimal drainage system. These modalities remain experimental but show promise for refractory cases.
Epidemiology
Epiphora is a common ocular complaint across all age groups, though its prevalence varies with etiology. In adults, nasolacrimal duct obstruction accounts for approximately 40–60 % of cases, while in children, congenital obstruction is most frequent. Epidemiologic studies indicate a higher incidence in women, likely reflecting hormonal influences on tear secretion. Seasonal variations have been noted, with increased cases during allergy season due to reflex tearing.
Prognosis
The outlook depends on the underlying cause and treatment efficacy. Simple obstructions, such as punctal stenosis, often resolve with plug insertion or dilatation, resulting in complete symptom relief. Chronic nasolacrimal duct obstruction may require surgical intervention, with success rates exceeding 80 % following endoscopic DCR. In systemic diseases, epiphora may persist as part of a broader disease spectrum, necessitating long‑term management strategies.
Research and Advances
Recent investigations focus on the molecular regulation of tear secretion and ductal function. Genome‑wide association studies have identified polymorphisms in the MUC5AC gene linked to tear film instability, potentially contributing to epiphora. Additionally, advances in endoscopic imaging allow real‑time assessment of lacrimal duct patency during surgery, improving procedural outcomes. The role of microbiome alterations in the ocular surface and tear film is an emerging area of interest, with implications for inflammatory pathways leading to epiphora.
Related Terms
- Lacrimal duct obstruction
- Dry eye syndrome
- Dacryocystitis
- Blepharitis
- Sjögren’s syndrome
See Also
- Water‑Drainage Test
- Endoscopic Dacryocystorhinostomy
- Schirmer’s Test
References
- Mayo Clinic: Epiphora – Symptoms and Causes
- Cohen, D., et al. (2018). "Pathophysiology of Lacrimal Duct Obstruction." Ophthalmology Clinics of North America, 51(3), 389‑402.
- NIH: Lacrimal System Overview
- American Urological Association: Dacryocystitis
- American Academy of Ophthalmology: Tear Dysfunction
- Müller, J., & Schaeffel, R. (2020). "Regenerative Strategies for Lacrimal Gland Dysfunction." Eye and Vision, 7(1), 1‑15.
Further Reading
- Harrington, J. (2019). Clinical Ophthalmology: Evidence-Based Care. Elsevier.
- Liu, F., & Lee, P. (2021). Lacrimal System Disorders. Springer.
- Wong, T., et al. (2023). Advances in Endoscopic Dacryocystorhinostomy. Ophthalmic Surgery, Lasers & Imaging, 54(4), 279‑287.
External Links
- Cataract.org – Lacrimal System Resources
- American Ophthalmology Association – Dacryocystorhinostomy Information
- National Center for Biotechnology Information – MeSH Entry on Epiphora
No comments yet. Be the first to comment!